EXACT SCIENCES CORP Form 10-Q May 15, 2009 Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2009

OR

0 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 000-32179

EXACT SCIENCES CORPORATION

(Exact name of registrant as specified in its charter)

DELAWARE

02-0478229

Edgar Filing: EXACT SCIENCES CORP - Form 10-Q

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification Number)

100 Campus Drive, Marlborough, Massachusetts (Address of principal executive offices)

01752 (Zip Code)

(508) 683-1200

(Registrant s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes £ No £

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting accelerated filer, and smaller reporting company in Rule 12b-2 of the Exchange Act. company. See the definitions of large accelerated filer,

Large accelerated filer o

Non-accelerated filer o (Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of May 15, 2009, the registrant had 30,887,484 shares of Common Stock outstanding.

Accelerated filer o

Smaller reporting company x

Table of Contents

EXACT SCIENCES CORPORATION

INDEX

		Page Number
	Part I - Financial Information	
Item 1.	Financial Statements	
	Condensed Consolidated Balance Sheets (Unaudited) as of March 31, 2009 and December 31, 2008	3
	Condensed Consolidated Statements of Operations (Unaudited) for the Three Months Ended March 31, 2009 and 2008	4
	Condensed Consolidated Statements of Cash Flows (Unaudited) for the Three Months Ended March 31, 2009 and 2008	5
	Notes to Condensed Consolidated Financial Statements (Unaudited)	6
<u>Item 2.</u>	Management s Discussion and Analysis of Financial Condition and Results of Operations	20
<u>Item 3.</u>	Quantitative and Qualitative Disclosures about Market Risk	26
Item 4T.	Controls and Procedures	26
	Part II - Other Information	
<u>Item 1A.</u>	Risk Factors	27
<u>Item 6.</u>	Exhibits	28
	Signatures	29
	Exhibit Index	30

2

Total stockholders deficit

EXACT SCIENCES CORPORATION

Condensed Consolidated Balance Sheets

(Amounts in thousands, except share data - unaudited)

		March 31, 2009		December 31, 2008
ASSETS				2000
Current Assets:				
Cash and cash equivalents	\$	3,595	\$	4,937
Marketable securities		17,018		, ·
Prepaid expenses and other current assets		690		190
Total current assets		21,303		5,127
Property and Equipment, at cost:		,		- , ·
Laboratory equipment		174		174
Office and computer equipment		22		13
Leasehold improvements				
Furniture and fixtures				
		196		187
Less Accumulated depreciation and amortization		(123)		(111)
		73		76
Patent costs, net of accumulated amortization of \$2,820 at December 31, 2008		15		95
Restricted cash		600		600
	\$	21,976	\$	5,898
LIABILITIES AND STOCKHOLDERS DEFICIT	Ψ	21,770	Ψ	5,070
Current Liabilities:				
Accounts payable	\$	34	\$	683
Accrued expenses	ψ	1,234	ψ	1,498
Third party royalty obligation, current portion		1,000		1,498
Deferred license fees, current portion		4,986		1,350
Total current liabilities		7,254		5,031
		7,234		5,051
Third party royalty obligation, less current portion		965		1,950
Deferred license fees, less current portion		14,901		1,350
		,,		-,
Commitments and contingencies				
Stockholders Deficit:				
Preferred stock, \$0.01 par value Authorized 5,000,000 shares Issued and outstanding 0 shares at March 31, 2009 and December 31, 2008, respectively				
Common stock, \$0.01 par value Authorized 100,000,000 shares Issued and				
outstanding 30,848,070 and 27,522,931 shares at March 31, 2009 and December 31, 2008,				
respectively		308		275
Additional paid-in capital		174,878		169,854
Treasury stock, at cost, 85,550 shares		(97)		(97)
Other comprehensive income		(97)		(97)
Accumulated deficit		(176,304)		(172,465)
		(170,504)		(1/2,403)

The accompanying notes are an integral part of these condensed consolidated financial statements.

(2, 433)

5,898

(1, 144)

21,976 \$

\$

Edgar Filing: EXACT SCIENCES CORP - Form 10-Q

Table of Contents

EXACT SCIENCES CORPORATION

Condensed Consolidated Statements of Operations

(Amounts in thousands, except per share data - unaudited)

	Three Months Ended March 2 2009 2		
Revenue:			
Product royalty fees	\$ 7	\$	(292)
License fees	993		338
Product			5
	1,000		51
Cost of revenue:			
Product royalty fees			1
Gross profit	1,000		50